Our highly specific and efficient enzymes can address current bottlenecks in DNA and RNA synthesis, enable novel molecular biology and diagnostic tools, and transform biopharma manufacturing efficiency to reduce cost and increase accessibility.
Resources on our planet are stretched and waste continues to accumulate – increasingly demanding a mindset change in how products are developed and manufactured. Our sustainable processes reduce waste and remove hazardous reagents from pharmaceutical manufacturing; our bio-based solutions for food, beverage & nutrition address increasing consumer demand for natural approaches; our high-performing enzymes for industrial applications reduce usage and drive processing efficiency. Explore novel approaches that benefit the triple bottom line – social, environmental, and financial.
Discovering and developing life-changing treatments for patients is our focus. By tailoring biotherapeutic performance using novel protein and gene therapies, we are well-positioned to address unmet medical needs and find treatments for a wide range of diseases and disorders.
Of people and the planet.
At Codexis, we strive to discover and develop more effective therapeutics, offer healthier choices, innovate sustainable processes and products, and reduce waste – all to create a brighter future.
These goals are grand but not beyond reach. Together with our business partners and loyal customers, we can make them a reality.
Molnupiravir (MK-4482) is an investigational antiviral agent that is under development for the treatment of COVID-19. The conversion of simple reagents into the 1st antiviral for COVID-19 was realized through the use of a multienzyme cascade made possible by the development of an efficient phosphate catalytic cycle.